Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast Period 2017 - 2025 And The Top Competitors Are Crown Bioscience, ProSpec Tany TechnoGene, BPS Bioscience, Sigma Aldrich Company, Novoprotein Scientific
Download The PDF Brochure : https://www.coherentmarketinsights.com/insight/request-pdf/1516
Increasing demand for recombinant proteins for basic research has supported growth of recombinant protein market. Manufacturers are involved in recombinant protein product innovation in order to improve research outcomes along with improvements in other areas such as expression techniques, and protein purification techniques, which compliments growth of the recombinant protein market. The market is expected to gain significant growth, owing increasing adoption of biologics and biosimilars, which will in turn impact recombinant proteins market, along with rising prevalence of chronic diseases such as cancer. Furthermore, availability of wide number of innovative recombinant proteins from various sources such as human and animal, lack of suitable alternative for basic protein related therapies research, and increasing demand for biological products is expected to fuel growth of the market.
Increasing research & development expenditure on biologic drugs is expected to boost demand for recombinant proteins for research purposes
Biopharmaceutical organizations are focusing on research and development of novel biosimilars for life threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and certain rare conditions such as hemophilia. According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S. Rare disease medical space holds potential as there is relatively low competition.
This is owing to less understanding of the disease progression pathways and entities. Therefore, companies could focus on R&D for development of biologics and subsequently biosimilars in this space. Some of the biosimilars available in the market include Eprex, manufactured by Janssen-Cilag Pty Ltd., which has been successful in treatment of anemia. Demand for biosimilars is increasing significantly, owing to high prices of biologics, in turn leading to high demand for recombinant protein.
Some major players operating in the recombinant protein market include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation.
Request For Customization : https://www.coherentmarketinsights.com/insight/request-customization/1516
Technological advancement in production of recombinant protein is expected to fuel growth of the recombinant protein market
Advancement in technologies in various areas associated with or facilitating recombinant protein production have supported growth of recombinant protein market. For instance, development of alternative expression technologies such as mammalian cell expression, baculovirus expression, and E.coli expression, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized recombinant protein processes. Furthermore, advanced chromatography protein purification methods such as FPLC and HPLC help in providing highly purified clinical grade recombinant proteins. Clustered regularly interspaced short palindromic repeats (CRISPR) technique is a genome editing technique used to target destruction in human cells and can improve recombinant protein production.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast Period 2017 - 2025 And The Top Competitors Are Crown Bioscience, ProSpec Tany TechnoGene, BPS Bioscience, Sigma Aldrich Company, Novoprotein Scientific here
News-ID: 1807329 • Views: 544
More Releases from Coherent Market Insights - Biotechnology
Wearable Patch Market 2030 Emerging Trends and Global Demand During the COVID-19 …
Coherent Market Insights published a report, titled,"Wearable Patch Market, by Technology (Connected and Regular), by Application (Monitoring, Drug Delivery, and Diagnostics), by End User (Healthcare and Fitness & Sports), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027." Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
Diabetes Vaccine Market Scrutinized in New Research 2018-2026
Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus
More Releases for Recombinant
Human Recombinant Insulin Market Growth Analysis
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry
Global Recombinant Factor VIII Market Research Report
This report studies the global Recombinant Factor VIII market status and forecast, categorizes the global Recombinant Factor VIII market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Shire (Baxter) Bayer CSL Pfizer Biogen Octapharma NovoNordisk Geographically, this report studies the top producers
United States Recombinant Vaccine Market Report
In this report, the United States Recombinant Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share
Recombinant DNA Technology Market -
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have
Global Human Recombinant Insulin Market – Industry Insights
Discovery of insulin is considered to be one of the most important events in the history of the diabetes treatment. Furthermore, major advances in human insulin technology is the synthesis of human insulin analogue by recombinant technology. Currently, human insulin delivery system available for the administration of insulin include insulin syringes, insulin pumps, jet injections, and pens. Key players are focused on developing recombinant human insulin instead of animal-based insulin,
Global Human Recombinant Insulin Market – Industry Insights
Various government and private research organizations are engaged research and development activities for developing advanced treatment in diabetes care to increase the effectiveness of human insulin, reduce diabetes burden, and minimize the risk of diabetes associated disorders such as diabetes-associated blindness, kidney disease, heart attacks, strokes or limb loss. For instance, American Diabetes Association (ADA) invested US$ 807.4 million in more than 4,700 research projects in diabetes research since 1952